325 related articles for article (PubMed ID: 32826319)
1. Peptide Receptor Radionuclide Therapy of Late-Stage Neuroendocrine Tumor Patients with Multiple Cycles of
Liu Q; Zang J; Sui H; Ren J; Guo H; Wang H; Wang R; Jacobson O; Zhang J; Cheng Y; Zhu Z; Chen X
J Nucl Med; 2021 Mar; 62(3):386-392. PubMed ID: 32826319
[TBL] [Abstract][Full Text] [Related]
2. Dose escalation of an Evans blue-modified radiolabeled somatostatin analog
Liu Q; Cheng Y; Zang J; Sui H; Wang H; Jacobson O; Zhu Z; Chen X
Eur J Nucl Med Mol Imaging; 2020 Apr; 47(4):947-957. PubMed ID: 31832728
[TBL] [Abstract][Full Text] [Related]
3. Safety and efficacy of peptide receptor radionuclide therapy with
Jiang Y; Liu Q; Wang G; Sui H; Wang R; Wang J; Zhang J; Zhu Z; Chen X
Theranostics; 2022; 12(15):6437-6445. PubMed ID: 36185603
[No Abstract] [Full Text] [Related]
4. Safety, Pharmacokinetics, and Dosimetry of a Long-Acting Radiolabeled Somatostatin Analog
Zhang J; Wang H; Jacobson O; Cheng Y; Niu G; Li F; Bai C; Zhu Z; Chen X
J Nucl Med; 2018 Nov; 59(11):1699-1705. PubMed ID: 29653971
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of Safety, Biodistribution, and Dosimetry of a Long-Acting Radiolabeled Somatostatin Analog 177 Lu-DOTA-EB-TATE With and Without Amino Acid Infusion.
Jiang Y; Liu Q; Wang G; Zhang J; Zhu Z; Chen X
Clin Nucl Med; 2023 Jun; 48(6):e289-e293. PubMed ID: 37075254
[TBL] [Abstract][Full Text] [Related]
6. First-in-Humans Study of the SSTR Antagonist
Baum RP; Zhang J; Schuchardt C; Müller D; Mäcke H
J Nucl Med; 2021 Nov; 62(11):1571-1581. PubMed ID: 33674401
[TBL] [Abstract][Full Text] [Related]
7. Estimation of Absorbed Doses of Indigenously Produced "Direct-route" Lutetium-177-[
Kamaldeep ; Loharkar S; Das T; Basu S; Banerjee S
Cancer Biother Radiopharm; 2022 Apr; 37(3):214-225. PubMed ID: 34910891
[No Abstract] [Full Text] [Related]
8. 177Lu-DOTATATE PRRT in Patients with Metastatic Neuroendocrine Tumor and a Single Functioning Kidney: Tolerability and Effect on Renal Function.
Ranade R; Basu S
J Nucl Med Technol; 2016 Jun; 44(2):65-9. PubMed ID: 26848166
[TBL] [Abstract][Full Text] [Related]
9. Salvage peptide receptor radionuclide therapy with [
van der Zwan WA; Brabander T; Kam BLR; Teunissen JJM; Feelders RA; Hofland J; Krenning EP; de Herder WW
Eur J Nucl Med Mol Imaging; 2019 Mar; 46(3):704-717. PubMed ID: 30267116
[TBL] [Abstract][Full Text] [Related]
10. Individualized peptide-related-radionuclide-therapy concept using different radiolabelled somatostatin analogs in advanced cancer patients.
Gabriel M; Andergassen U; Putzer D; Kroiss A; Waitz D; Von Guggenberg E; Kendler D; Virgolini IJ
Q J Nucl Med Mol Imaging; 2010 Feb; 54(1):92-9. PubMed ID: 20168291
[TBL] [Abstract][Full Text] [Related]
11. Clinical Response Profile of Metastatic/Advanced Pulmonary Neuroendocrine Tumors to Peptide Receptor Radionuclide Therapy with 177Lu-DOTATATE.
Parghane RV; Talole S; Prabhash K; Basu S
Clin Nucl Med; 2017 Jun; 42(6):428-435. PubMed ID: 28319500
[TBL] [Abstract][Full Text] [Related]
12. Response to Single Low-dose
Wang H; Cheng Y; Zhang J; Zang J; Li H; Liu Q; Wang J; Jacobson O; Li F; Zhu Z; Chen X
Theranostics; 2018; 8(12):3308-3316. PubMed ID: 29930731
[No Abstract] [Full Text] [Related]
13. Efficacy of [
Njotu FN; Ketchemen JP; Tikum AF; Babeker H; Gray BD; Pak KY; Uppalapati M; Fonge H
J Nucl Med; 2024 Apr; 65(4):533-539. PubMed ID: 38485273
[TBL] [Abstract][Full Text] [Related]
14. Peptide receptor radionuclide therapy (PRRT) in metastatic neuroendocrine tumors of unknown primary (CUP-NETs).
Baum RP; Wang P; Jakobsson V; Zhao T; Schuchardt C; Khong PL; Zhang J
Theranostics; 2024; 14(1):133-142. PubMed ID: 38164147
[No Abstract] [Full Text] [Related]
15. Salvage PRRT with
Rudisile S; Gosewisch A; Wenter V; Unterrainer M; Böning G; Gildehaus FJ; Fendler WP; Auernhammer CJ; Spitzweg C; Bartenstein P; Todica A; Ilhan H
BMC Cancer; 2019 Aug; 19(1):788. PubMed ID: 31395036
[TBL] [Abstract][Full Text] [Related]
16. Long-term outcome of "Sandwich" chemo-PRRT: a novel treatment strategy for metastatic neuroendocrine tumors with both FDG- and SSTR-avid aggressive disease.
Parghane RV; Ostwal V; Ramaswamy A; Bhandare M; Chaudhari V; Talole S; Shrikhande SV; Basu S
Eur J Nucl Med Mol Imaging; 2021 Mar; 48(3):913-923. PubMed ID: 32876706
[TBL] [Abstract][Full Text] [Related]
17. Personalized
Del Prete M; Buteau FA; Arsenault F; Saighi N; Bouchard LO; Beaulieu A; Beauregard JM
Eur J Nucl Med Mol Imaging; 2019 Mar; 46(3):728-742. PubMed ID: 30506283
[TBL] [Abstract][Full Text] [Related]
18. Metastatic Neuroendocrine Tumor with Extensive Bone Marrow Involvement at Diagnosis: Evaluation of Response and Hematological Toxicity Profile of PRRT with (177)Lu-DOTATATE.
Basu S; Ranade R; Thapa P
World J Nucl Med; 2016; 15(1):38-43. PubMed ID: 26912977
[TBL] [Abstract][Full Text] [Related]
19. Treatment with tandem [90Y]DOTA-TATE and [177Lu]DOTA-TATE of neuroendocrine tumours refractory to conventional therapy.
Seregni E; Maccauro M; Chiesa C; Mariani L; Pascali C; Mazzaferro V; De Braud F; Buzzoni R; Milione M; Lorenzoni A; Bogni A; Coliva A; Lo Vullo S; Bombardieri E
Eur J Nucl Med Mol Imaging; 2014 Feb; 41(2):223-30. PubMed ID: 24233003
[TBL] [Abstract][Full Text] [Related]
20. Long-term Nephrotoxicity after PRRT: Myth or Reality.
Baum RP; Fan X; Jakobsson V; Yu F; Schuchardt C; Chen X; Zhang J
Theranostics; 2024; 14(2):451-459. PubMed ID: 38169589
[No Abstract] [Full Text] [Related]
[Next] [New Search]